Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline.
To start, the companies will design and develop a biomarker test aimed at neuroscience programs, and multiple sclerosis specifically—a treatment area that they expect to expand into a $23.5 billion global market by 2025.
The initial immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, which are linked to nerve cell injury and a variety of neurological conditions including MS.
Levels of neurofilament light chain in the blood have also been associated with various clinical measures of MS activity and MRI scans showing nerve damage. As a chronic inflammatory disease of the central nervous system, MS sees destruction of neurons’ protective myelin sheath across the brain, optic nerves and spinal cord.
In August, the FDA approved Novartis’ MS treatment Kesimpta for both the relapsing-remitting and secondary progressive forms of the disease. The drug, already approved in leukemia as Arzerra, targets particular immune system B cells expressing CD20.
Earlier this year, Novartis presented data for Mayzent, an S1P receptor modulator for secondary progressive MS, showing that early treatment could slow the course of the disease. However, in many cases, patients and doctors may not be aware that the disease has moved into the secondary progressive stage, and it is often diagnosed late as symptoms become more apparent.
“We are looking forward to our collaboration with Novartis as it promises to yield innovative diagnostic solutions to address critical unmet clinical needs,” said Deepak Nath, president of laboratory diagnostics for Siemens Healthineers.
By: Conor Hale
Source: Fierce Biotech
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”